Form 4: Adaptive Biotechnologies President Executes Stock Plan

President and COO Julie Rubinstein exercised options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies, exercised stock options for 44,166 shares at a strike price of $8.46 between April 14 and April 16, 2026.
• Following the exercises, she sold a total of 57,180 shares at weighted average prices ranging from $14.18 to $14.61 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025.
• The reporting person's direct beneficial ownership of common stock stands at 408,160 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine executive financial management.

Positives

• Transactions were executed under a pre-planned Rule 10b5-1 program, indicating systematic rather than reactive selling.
• The executive maintains a significant remaining stake of 408,160 shares in the company.

Negatives

• The executive reduced her total beneficial ownership through the net sale of shares.

Risks

• Future share price volatility could impact the value of remaining unvested options.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transactions.

Industry Context

StockSavvy.ai notes that insider selling via Rule 10b5-1 plans is a standard practice for executives to manage personal liquidity and diversify holdings without triggering concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives at publicly traded biotech firms to ensure compliance with SEC regulations.
• The volume of shares sold relative to the total holdings is consistent with typical executive compensation and liquidity management patterns.

Stakeholder Impact

• Minimal impact expected on shareholders as the sales were conducted under a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Julie Rubinstein, Stock Options, Rule 10b5-1